Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018107116) METHODS OF REDUCING TOXICITY OF ANTIBODY DRUG CONJUGATES, AND COMPOSITIONS PRODUCED THEREBY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/107116 International Application No.: PCT/US2017/065455
Publication Date: 14.06.2018 International Filing Date: 08.12.2017
IPC:
A61K 38/00 (2006.01) ,A61K 39/00 (2006.01) ,A61K 39/395 (2006.01) ,A61K 47/48 (2006.01) ,A61K 47/68 (2017.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
48
the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
[IPC code unknown for A61K 47/68]
Applicants:
ABBVIE STEMCENTRX LLC [US/US]; 1 North Waukegan Road North Chicago, IL 60064, US
Inventors:
LIU, David; US
Agent:
MEIGS, Julie Broadus; US
TIMM, Russell, S.; US
RAY, Denise, M.; US
MOORE, Jake; US
Priority Data:
62/432,07309.12.2016US
Title (EN) METHODS OF REDUCING TOXICITY OF ANTIBODY DRUG CONJUGATES, AND COMPOSITIONS PRODUCED THEREBY
(FR) PROCÉDÉS DE RÉDUCTION DE LA TOXICITÉ DE CONJUGUÉS ANTICORPS-MÉDICAMENT, ET COMPOSITIONS PRODUITES PAR CEUX-CI
Abstract:
(EN) This application provides antibodies, immunoreactive fragments thereof, having modifications such as amino acid deletions and/or substitutions within their constant region (Fc), and antibody drug conjugates (ADCs) comprising said modified antibodies or immunoreactive fragments, having effective anti-cancer activity while exhibiting improved pharmacokinetic and toxicity profiles.
(FR) La présente invention concerne des anticorps, des fragments immunoréactifs de ceux-ci, ayant des modifications telles que des délétions et/ou des substitutions d'acides aminés dans leur région constante (Fc), et des conjugués anticorps-médicament (ADC) comprenant lesdits anticorps modifiés ou fragments immunoréactifs, ayant une activité anticancéreuse efficace tout en présentant des profils pharmacocinétiques et de toxicité améliorés.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)